Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate Long-Term Safety and Efficacy of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Alvimopan (Primary)
- Indications Intestinal disorders
- Focus Adverse reactions; Registrational
- Sponsors Cubist Pharmaceuticals; GlaxoSmithKline; GSK
- 02 Nov 2012 New source identifiued and integrated (European Clinical Trials Database; EudraCT2005-001725-28).
- 21 Dec 2011 New trial record